S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
Log in
NASDAQ:NMTR

9 Meters Biopharma Stock Forecast, Price & News

$1.38
-0.01 (-0.72 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.20
Now: $1.38
$1.43
50-Day Range
$1.07
MA: $1.61
$2.16
52-Week Range
$0.44
Now: $1.38
$2.26
Volume8.45 million shs
Average Volume13.17 million shs
Market Capitalization$207.45 million
P/E RatioN/A
Dividend YieldN/A
Beta0.11
9 Meters Biopharma, Inc., a clinical-stage biotechnology company, focuses on patients with rare disorders and unmet needs. The company's pipeline includes drug candidates for short bowel syndrome (SBS) and celiac disease. It is developing NM-002, a long-acting injectable GLP-1 agonist that is in a Phase 2 clinical trial for SBS; and Larazotide, a Phase 3-stage therapeutic in development for celiac disease. The company also develops NM-003, a proprietary long-acting GLP-2 agonist; and NM-004, a double-cleaved mesalamine with an immunomodulator for developing rare and/or orphan indications. 9 Meters Biopharma, Inc. is based in Raleigh, North Carolina.
9 Meters Biopharma logo

Headlines

9 Meters Biopharma (NMTR) is Overbought: Is A Drop Coming?
February 4, 2021 |  finance.yahoo.com
9 Meters Biopharma Inc.
January 5, 2021 |  barrons.com
Is 9 Meters Biopharma (NMTR) A Good Stock To Buy Now?
December 2, 2020 |  finance.yahoo.com
Insider Buys 9 Meters Biopharma Shares
September 15, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NMTR
CUSIPN/A
CIKN/A
Phone919-275-1933
Employees8
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($0.27) per share

Profitability

Net Income$-27,050,000.00

Miscellaneous

Market Cap$207.45 million
Next Earnings Date3/8/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.44 out of 5 stars

Medical Sector

577th out of 1,972 stocks

Pharmaceutical Preparations Industry

267th out of 772 stocks

Analyst Opinion: 3.5Community Rank: 3.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$1.38
-0.01 (-0.72 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NMTR News and Ratings via Email

Sign-up to receive the latest news and ratings for NMTR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











9 Meters Biopharma (NASDAQ:NMTR) Frequently Asked Questions

Is 9 Meters Biopharma a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 9 Meters Biopharma in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" 9 Meters Biopharma stock.
View analyst ratings for 9 Meters Biopharma
or view top-rated stocks.

What stocks does MarketBeat like better than 9 Meters Biopharma?

Wall Street analysts have given 9 Meters Biopharma a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but 9 Meters Biopharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting 9 Meters Biopharma?

9 Meters Biopharma saw a drop in short interest during the month of February. As of February 12th, there was short interest totaling 3,640,000 shares, a drop of 36.7% from the January 28th total of 5,750,000 shares. Based on an average daily volume of 10,650,000 shares, the short-interest ratio is currently 0.3 days. Approximately 1.9% of the company's shares are sold short.
View 9 Meters Biopharma's Short Interest
.

When is 9 Meters Biopharma's next earnings date?

9 Meters Biopharma is scheduled to release its next quarterly earnings announcement on Monday, March 8th 2021.
View our earnings forecast for 9 Meters Biopharma
.

How were 9 Meters Biopharma's earnings last quarter?

9 Meters Biopharma, Inc. (NASDAQ:NMTR) released its earnings results on Saturday, November, 14th. The company reported ($0.06) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.06).
View 9 Meters Biopharma's earnings history
.

What price target have analysts set for NMTR?

6 brokerages have issued 1 year target prices for 9 Meters Biopharma's shares. Their forecasts range from $5.00 to $6.00. On average, they anticipate 9 Meters Biopharma's share price to reach $5.25 in the next year. This suggests a possible upside of 280.4% from the stock's current price.
View analysts' price targets for 9 Meters Biopharma
or view top-rated stocks among Wall Street analysts.

Who are 9 Meters Biopharma's key executives?

9 Meters Biopharma's management team includes the following people:
  • Dr. Patrick H. Griffin, Chief Medical Officer (Age 66, Pay $513.12k)
  • Mr. John Temperato, Pres, CEO & Director (Age 55)
  • Mr. Edward J. Sitar CPA, CPA, Chief Financial Officer (Age 58)
  • Mr. Sireesh Appajosyula Pharm.D., Sr. VP of Corp. Devel. & Operations
  • Jerry Gardner, Head of Clinical Strategy
  • Dr. Nir Barak, Sr. VP of Scientific Affairs
  • Dr. Peter H. R. Green M.D., Clinical & Scientific Advisor and Consultant
  • Mr. Joseph A. Murray, Clinical & Scientific Advisor and Consultant
  • Dr. Ciaran P. Kelly M.D., Clinical & Scientific Advisor and Consultant
  • Dr. Elena Verdu M.D., Ph.D., Clinical & Scientific Advisor and Consultant

Who are some of 9 Meters Biopharma's key competitors?

What other stocks do shareholders of 9 Meters Biopharma own?

What is 9 Meters Biopharma's stock symbol?

9 Meters Biopharma trades on the NASDAQ under the ticker symbol "NMTR."

Who are 9 Meters Biopharma's major shareholders?

9 Meters Biopharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (2.02%), Tri Locum Partners LP (0.93%), Worth Venture Partners LLC (0.53%), HN Saltoro Capital LP (0.47%), Renaissance Technologies LLC (0.42%) and Perkins Capital Management Inc. (0.20%). Company insiders that own 9 Meters Biopharma stock include John Temperato and Mark A Sirgo.
View institutional ownership trends for 9 Meters Biopharma
.

Which major investors are selling 9 Meters Biopharma stock?

NMTR stock was sold by a variety of institutional investors in the last quarter, including ExodusPoint Capital Management LP.
View insider buying and selling activity for 9 Meters Biopharma
or view top insider-selling stocks.

Which major investors are buying 9 Meters Biopharma stock?

NMTR stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Tri Locum Partners LP, Worth Venture Partners LLC, HN Saltoro Capital LP, Perkins Capital Management Inc., Renaissance Technologies LLC, Creative Planning, and Northern Trust Corp. Company insiders that have bought 9 Meters Biopharma stock in the last two years include John Temperato, and Mark A Sirgo.
View insider buying and selling activity for 9 Meters Biopharma
or or view top insider-buying stocks.

How do I buy shares of 9 Meters Biopharma?

Shares of NMTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is 9 Meters Biopharma's stock price today?

One share of NMTR stock can currently be purchased for approximately $1.38.

How much money does 9 Meters Biopharma make?

9 Meters Biopharma has a market capitalization of $207.45 million.

How many employees does 9 Meters Biopharma have?

9 Meters Biopharma employs 8 workers across the globe.

What is 9 Meters Biopharma's official website?

The official website for 9 Meters Biopharma is www.9meters.com.

Where are 9 Meters Biopharma's headquarters?

9 Meters Biopharma is headquartered at 8480 HONEYCUTT ROAD SUITE 120, RALEIGH NC, 27615.

How can I contact 9 Meters Biopharma?

9 Meters Biopharma's mailing address is 8480 HONEYCUTT ROAD SUITE 120, RALEIGH NC, 27615. The company can be reached via phone at 919-275-1933 or via email at [email protected]


This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.